## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	)
Hirokazu ANNOURA et al.	) Group Art Unit: Unassigned
Application No.: Divisional of Application No.10/196,362	) <ul><li>Examiner: Unassigned</li></ul>
·	) Confirmation No.: Unassigned
Filed: March 15, 2004	)
	)
For: ARYLPIPERIDINOL AND	)
ARYLPIPERIDINE DERIVATIVES	)
AND PHARMACEUTICALS	)
CONTAINING THE SAME	)

## FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98.

All of the listed documents were previously made of record in prior Application Serial No. 10/196,362, filed July 17, 2002, upon which Applicants rely for the benefits provided in 35 U.S.C. § 120. In accordance with 37 C.F.R. § 1.98, copies of the listed documents are not included.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: March 15, 2004

Susan M. Dadio

Registration No. 40,373

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Substitute for forms 1449A/PTO & 1449B/PTO	ATTORNEY'S DKT No. 001560-454	APPLICATION No. Divisional of Application No. 10/196,362
FIRST INFORMATION DISCLOSURE	APPLICANT Hirokzau ANNOURA et al.	
STATEMENT BY APPLICANT	FILING DATE March 15, 2004	GROUP Unassigned

		, ,	J.S. PATENT DOCUMENTS				
Examiner	Number (if known) of Cited Document				Issue/Publication Date (MM-DD-YYYY)		
Initials							
	3,301,862		BIEL et al.		01-31-1967		
	3,350,403		BIEL		10-31-1967		
	4,241,071		MARTIN et al.			-23-1980	
	5,019,582	-	DREJER et al. 05-28-19				
	5,723,475		ANNOURA et al. 03-03-19				
	6,048,876		ANNOURA et al. 04-		4-11-2000		
				·			
		FOF	REIGN PATENT DOCUMENTS				
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publica (MM-DD-YYY		Trans Yes	latior No
	0 757 986	٠.	Europe	02-12-199	7		
	0 755 923	-	Europe	01-23-199	7		
	0 339 579		Europe	11-02-198	9		
	0 494 717		Europe	07-15-199	2		
	95/24390		WO	09-14-199	5		
	2 706 894		France	12-30-199	4		
	96/22977		WO (Abstract)	01-08-199	6		
	96/26924		WO (Abstract)	06-09-199	6		
	63-126866		Japan (Abstract)	05-20-198	8		
	1-313461		Japan (Abstract)	12-18-198	9		
	53-95963		Japan	03-22-197	8		
		NON PA	TENT LITERATURE DOCUMENTS	· · · · · · · · · · · · · · · · · · ·			
Examiner Initials	item (boo	k, magazine, jourr	(in CAPITAL LETTERS), title of the article (whe nal, serial, symposium, catalog, etc.), date, page publisher, city and/or country where published	e(s), volume-issue r	numbe		
			cinal Chemistry, Vol. 22, No. 11, pp. 13				
			licinal Chemistry, Vol. 40, pp. 1982-198				
			ardiovascular Pharmacology, Vol. 18, N	lo. 6, pp. 918-9	25, 19	991	
	CELKOVA et al.,	, Pharmazie, V	ol. 52, No. 6, pp. 487-488, 1997.	<u>.</u>			
		· · · · · · · · · · · · · · · · · · ·					
	1						

		<del></del>
Examiner	Date	
Signature	 Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.